Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Delayed Nasdaq
Other stock markets
 09:32:50 20/06/2024 pm IST 		5-day change 1st Jan Change
0.7342 USD +3.41% Intraday chart for MIRA Pharmaceuticals, Inc. +3.39% -30.08%
10/06 MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year CI
29/05 Sector Update: Health Care Stocks Fall Late Afternoon MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
PR
MIRA Pharmaceuticals, Inc. Announces Positive Preclinical Study Results for Its Novel Oral Ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
CI
Sector Update: Health Care Stocks Fall Late Afternoon
MT
Sector Update: Health Care Stocks Retreat Wednesday Afternoon
MT
Mira Pharmaceuticals Says US DEA Finds Marijuana Analog a Non-Controlled Substance
MT
Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
PR
MIRA Pharmaceuticals, Inc. Announces DEA Rules Mira-55, A Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as A Controlled Substance
CI
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
PR
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
PR
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog
CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
PR
Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
PR
Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor
CI
MIRA Pharmaceuticals, Inc. Announces Management Changes
CI
MIRA Pharmaceuticals, Inc. Provides Updated Information Regarding the Patented, Pre-Clinical Drug Candidate Molecule Known as Mira1a
CI
MIRA Pharmaceuticals Provides Corporate Update
PR
Certain Stock Options of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. News MIRA Pharmaceuticals, Inc.